Inotek Pharmaceuticals Corp Share Price Nasdaq
Equities
US45780V1026
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- | - |
Sales 2024 * | 26.32M 0 2.19B | Sales 2025 * | 163M 0 13.58B | Capitalization | 2.03B 0 169B |
---|---|---|---|---|---|
Net income 2024 * | -260M - -21.64B | Net income 2025 * | -219M - -18.22B | EV / Sales 2024 * | 69.7 x |
Net cash position 2024 * | 193M 0 16.06B | Net cash position 2025 * | 111M 0 9.28B | EV / Sales 2025 * | 11.7 x |
P/E ratio 2024 * |
-8.24
x | P/E ratio 2025 * |
-10.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.59% |
Latest transcript on Inotek Pharmaceuticals Corp
Managers | Title | Age | Since |
---|---|---|---|
Gaurav D. Shah
CEO | Chief Executive Officer | 49 | 04/18/04 |
Kinnari Patel
PSD | President | 46 | 04/18/04 |
Chief Tech/Sci/R&D Officer | 60 | 01/16/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pedro Granadillo
BRD | Director/Board Member | 77 | 04/18/04 |
Carsten Boess
BRD | Director/Board Member | 57 | 01/16/01 |
David Southwell
BRD | Director/Board Member | 63 | 01/14/01 |
1st Jan change | Capi. | |
---|---|---|
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-2.50% | 21.28B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
+33.90% | 12.2B | |
-28.60% | 7.83B |